Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Martin Eilers
Fatty acid channelling into triglycerides and oxylipins drives ferroptosis resistance during oncogenic BRAF-induced senescence
Abstract Oncogene-induced senescence (OIS), a cellular programme initiated by activation of oncogenic signalling, provides a barrier to transformation and is accompanied by major reprogramming of cellular metabolism.
Riboflavin metabolism shapes FSP1-driven ferroptosis resistance
|
Abstract Membrane protection against oxidative insults is achieved by the concerted action of glutathione peroxidase 4 (GPX4) and endogenous lipophilic antioxidants such as ubiquinone and vitamin E. More recently, ferroptosis suppressor protein 1 (FSP1) was identified as a critical ferroptosis inhibitor, acting via the regeneration of membrane-embedded antioxidants.
By Izadora de Souza, Biplab Ghosh, Florencio Porto Freitas, Zhiyi Chen, Shibo Sun, Palina Nepachalovich, Juliane Tschuck, Apoorva Mathur, Ariane Nunes-Alves, Jannik Buhr, Camilo Aponte-Santamaría, Werner Schmitz, Matthias Mack, Martin Eilers, Ralf Bargou, Milena Chaufan, Mayher Kaur, Mario Palma, Jessalyn M. Ubellacker, Ulrich Elling, Hellmut G. Augustin, Kamyar Hadian, Svenja Meierjohann, Bettina Proneth, Marcus Conrad, Maria Fedorova, Hamed Alborzinia, Vera Skafar, Merce Donate Castillo, Lars Seufert, Sebastian Bothe
|
Nature
Verified
MYC binding to nascent RNA suppresses innate immune signaling by R-loop-derived RNA-DNA hybrids Original
|
Keywords MYC RNA binding TLR3 TBK1 R-loop exosome innate immune signaling pancreatic ductal adenocarcinoma PDAC Introduction The MYC protein is an oncogenic driver in many tumor entities.1 Relative to normal tissues, MYC expression is enhanced in human tumors due to mutations in the MYC gene or as a downstream consequence of a plethora of alterations in signaling pathways that collectively control MYC expression.
By Leonie Uhl, Amel Aziba, Sinah Löbbert, Timothy Donavan Russell, Bastian Krenz, Francisco Montesinos, Toshitha Kannan, Omkar R. Valanju, Christina Schülein-Völk, Tim de Martines, Michael Bolz, Daniel Fleischhauer, Giacomo Cossa, Theresa Endres, Daniel Solvie, Peter Gallant, Andreas Rosenwald, Hans M. Maric, Dimitrios Papadopoulos, Seychelle M. Vos, Martin Eilers
|
Cell Press
Verified
Correction: USP10 drives cancer stemness and enables super-competitor signalling in colorectal cancer - Oncogene
The affiliation of the author Gerti Beliu has been corrected from “Institute of Lung Health and Immunity, Helmholtz Center, Munich, Germany” to “Rudolf-Virchow-Center for Integrative and Translational Imaging, University of Wuerzburg, Wuerzburg, Germany.” The original article has been corrected.
USP28 controls SREBP2 and the mevalonate pathway to drive tumour growth in squamous cancer - Cell Death & Differentiation
Tissue culture and reagents Cell lines were obtained from ATCC (American Type Culture Collection, Chicago, IL, USA) and used at low passage. Cells were cultured in DMEM (A431, U2OS, HEK293T) or RPMI 1640 (NCI-H520, LUDLU1, CALU-1, NCI-H522, NCI-H1299, A549) supplemented with 10% foetal calf serum (FCS), 2 mmol/L glutamine and 100 U/mL penicillin/streptomycin (all Sigma). Delipidated FCS was prepared as previously described [23].
Drugging the “Undruggable” MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers
Review Adam J. Wolpaw, Richard Bayliss, Gabriele Büchel, Chi V. Dang, Martin Eilers, W. Clay Gustafson, Gwenn H. Hansen, Natalia Jura, Stefan Knapp, Mark A. Lemmon, David Levens, John M. Maris, Ronen Marmorstein, Steven J. Metallo, Julie R. Park, Linda Z. Penn, Michael Rape, Martine F. Roussel, Kevan M. Shokat, William P. Tansey, Kliment A. Verba, Seychelle M. Vos, William A. Weiss, Elmar Wolf and Yaël P.
Drugging the 'undruggable' MYCN oncogenic transcription factor: Overcoming previous obstacles to impact childhood cancers
Review Adam J. Wolpaw, Richard Bayliss, Gabriele Büchel, Chi V. Dang, Martin Eilers, W. Clay Gustafson, Gwenn M. Hansen, Natalia Jura, Stefan Knapp, Mark A. Lemmon, David Levens, John M. Maris, Ronen Marmorstein, Steven J. Metallo, Julie R. Park, Linda Z. Penn, Michael Rape, Martine F. Roussel, Kevan M. Shokat, William P. Tansey, Kliment A. Verba, Seychelle M. Vos, William A. Weiss, Elmar Wolf and Yaël P.
The Expanding World of N-MYC-Driven Tumors
IntroductionThe human MYC gene (encoding the C-MYC protein) was first identified as the cellular homolog of an avian retroviral transforming gene, v-myc (1). It is the founding member of a small gene family, including two closely related genes, MYCN (encoding N-MYC) and MYCL (encoding L-MYC), identified in neuroblastoma and in small cell lung cancer (SCLC), respectively (2–4).
|
By Khin Thway, Simon Robinson Verified, Matthias Fischer Verified, Markus Brockmann, Evon Poon, Teeara Berry, Anne Carstensen, Hedwig E. Deubzer, Lukas Rycak, Yann Jamin, Frederik Roels, Olaf Witt, Louis Chesler, Martin Eilers
|
secure.jbs.elsevierhealth.com
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Martin
Contact Martin, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack